Efficacy and safety of Stereotactic ablative radiotherapy (SABR) in oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) patients during abiraterone therapy.

Trial Profile

Efficacy and safety of Stereotactic ablative radiotherapy (SABR) in oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) patients during abiraterone therapy.

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Abiraterone (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Oct 2017 New trial record
    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top